search
Back to results

Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine

Primary Purpose

Migraine

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Relivion®
Sponsored by
Neurolief Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Subjects 18 years of age and older. Subject meets the ICHD-3 (2018) diagnostic criteria for either Episodic migraine (<15 headache (HA) days/month) or Chronic (at least 15 days of HA/month with at least 8 days/month migraine days (migraine with and without aura) for > 3 months). Subject migraine age of onset <50 years of age. History of 6 to 24 headache days on average per month for the 3 months preceding study enrolment (based on participant report). Completed at least 21 out of 28 days in the eDiary during run-in period. Partially completed data for the run-in period will be adjusted to reflect an estimated number of days with the outcome of interest per 28-day interval by using the formula (28/x)*y, where x is the number of days with observed data per 28-day period and y is the number of observed days with the outcome of interest. Subject reports 6-24 headache days per 28 days, confirmed by 28 days or adjusted 28 days baseline diary. Subjects on prophylactic migraine treatment are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the screening visit, and the dose is not expected to change during the course of the study. Subject is willing to and capable of complying with the specified study requirements, provided written Informed Consent can complete the electronic diaries, and can be contacted by telephone. Exclusion Criteria: Initiating or changing the type, dosage, or frequency of any medications for other indications than migraine that are determined to potentially interfere with the study. Failure on ≥2 well-conducted preventive treatments. A treatment failure (lack of efficacy) trial is characterized as a Level A or Level B evidence-based preventive treatment (medications or a MAB or preventive gepant) for migraine preventive trial taken for a minimum of 2 months, at a minimally adequate dose, that produced less than 50% improvement in MMD reduction). Failure to tolerate a preventive treatment does not constitute a preventive treatment failure. History of other chronic headache conditions such as Chronic tension-type headache, Medication Overuse Headache, New Daily Persistent Headache, and Cluster Headache in the prior 6 months. Use of opiates or barbiturates medications in the prior 3 months. Received parenteral infusions for migraine within the previous 2 weeks. Subject has known uncontrolled epilepsy. History of neuro-interventional procedures such as nerve blocks (within the last month), Botulinum Toxin (within the last 3-months), neurosurgical interventions in the head or neck, or implanted/wearable neurostimulators, electronic devices in the head, cardiac pacemaker, surgical clips above the shoulder line or medical pumps, except for dental implants. Current drug abuse or alcoholism. Subjects participating in other clinical trials evaluating experimental treatments or procedures. Skin lesion, scars, or inflammation in the region of the stimulating electrodes. Personality or somatoform disorder. Pregnancy or Lactation. Women of reproductive age not using a reliable contraceptive method, as determined by the Investigator (NOTE: Females of childbearing potential must have a negative pregnancy test). Documented history of cerebrovascular event. Subject with a recent history of traumatic brain injury (TBI), defined as a disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury, within 3 months of study enrollment. Subjects who demonstrate or have a history of any cognitive disorder or impairment, memory loss, dementia, confusion or delirium that, in the opinion of the Investigator, may compromise the integrity of the study data or impact the ability of the subject to comply with the study requirements. Subject diagnosed with other chronic pain disorder which in the opinion of the Investigator may compromise the integrity of the study data or impact the ability of the subject to comply with the study requirements. The subject does not have the basic cognitive and motor skills needed to operate a smartphone. Subject with head circumference smaller than 51 centimeters or head circumference larger than 60 centimeters.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Active stimulation

    Arm Description

    Relivion® device- Active stimulation

    Outcomes

    Primary Outcome Measures

    Mean change in Monthly Migraine Days (MMD).
    Mean change from baseline (M0) in Monthly Migraine Days (MMD) comparing with the last 28 treatment days (M3: weeks 9-12).

    Secondary Outcome Measures

    Proportion of responder subjects
    Proportion of responder subjects defined as the percent of subjects achieving at least 50% reduction from baseline (M0) in their monthly migraine days comparing with the last 28 treatment days (M3: weeks 9-12).
    Mean change in monthly acute anti-migraine headache drug days.
    Mean change in baseline (M0) monthly acute anti-migraine headache drug days comparing with the last 28 treatment days (M3: weeks 9-12).
    Mean change total headache days.
    Mean change in baseline (M0) total headache days comparing with the last 28 treatment days (M3: weeks 9-12)

    Full Information

    First Posted
    March 26, 2023
    Last Updated
    June 12, 2023
    Sponsor
    Neurolief Ltd.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05804396
    Brief Title
    Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine
    Official Title
    The SP-303 PERL Study - Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2023 (Anticipated)
    Primary Completion Date
    December 2023 (Anticipated)
    Study Completion Date
    December 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Neurolief Ltd.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Device Product Not Approved or Cleared by U.S. FDA
    Yes
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The PERL Study will evaluate the safety and efficacy of a self-administered preventive treatment for migraine headache using combined occipital and trigeminal nerve stimulation (Relivion®). This is a prospective, non-randomized, single arm, multi-center study designed to evaluate the use of Relivion® in reducing the frequency of headache days against a sham performance goal.
    Detailed Description
    The study will include the following study visits & phases: Visit 1 Screening Run-in (Baseline) Period - Daily migraine headache diary. Visit 2 Enrollment -Study enrollment, device and regimen training. Treatment Period- Relivion® migraine preventive treatment for 12 consecutive weeks. Patients will be required to fill in a daily migraine diary. Visit 3 Follow Up Visit. Visit 4 Follow Up Visit. Visit 5 End of study. After completion of visit 5 the subject's participation will be over.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Migraine

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    57 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Active stimulation
    Arm Type
    Experimental
    Arm Description
    Relivion® device- Active stimulation
    Intervention Type
    Device
    Intervention Name(s)
    Relivion®
    Intervention Description
    Active stimulation device
    Primary Outcome Measure Information:
    Title
    Mean change in Monthly Migraine Days (MMD).
    Description
    Mean change from baseline (M0) in Monthly Migraine Days (MMD) comparing with the last 28 treatment days (M3: weeks 9-12).
    Time Frame
    3 months
    Secondary Outcome Measure Information:
    Title
    Proportion of responder subjects
    Description
    Proportion of responder subjects defined as the percent of subjects achieving at least 50% reduction from baseline (M0) in their monthly migraine days comparing with the last 28 treatment days (M3: weeks 9-12).
    Time Frame
    3 months
    Title
    Mean change in monthly acute anti-migraine headache drug days.
    Description
    Mean change in baseline (M0) monthly acute anti-migraine headache drug days comparing with the last 28 treatment days (M3: weeks 9-12).
    Time Frame
    3 months
    Title
    Mean change total headache days.
    Description
    Mean change in baseline (M0) total headache days comparing with the last 28 treatment days (M3: weeks 9-12)
    Time Frame
    3 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subjects 18 years of age and older. Subject meets the ICHD-3 (2018) diagnostic criteria for either Episodic migraine (<15 headache (HA) days/month) or Chronic (at least 15 days of HA/month with at least 8 days/month migraine days (migraine with and without aura) for > 3 months). Subject migraine age of onset <50 years of age. History of 6 to 24 headache days on average per month for the 3 months preceding study enrolment (based on participant report). Completed at least 21 out of 28 days in the eDiary during run-in period. Partially completed data for the run-in period will be adjusted to reflect an estimated number of days with the outcome of interest per 28-day interval by using the formula (28/x)*y, where x is the number of days with observed data per 28-day period and y is the number of observed days with the outcome of interest. Subject reports 6-24 headache days per 28 days, confirmed by 28 days or adjusted 28 days baseline diary. Subjects on prophylactic migraine treatment are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the screening visit, and the dose is not expected to change during the course of the study. Subject is willing to and capable of complying with the specified study requirements, provided written Informed Consent can complete the electronic diaries, and can be contacted by telephone. Exclusion Criteria: Initiating or changing the type, dosage, or frequency of any medications for other indications than migraine that are determined to potentially interfere with the study. Failure on ≥2 well-conducted preventive treatments. A treatment failure (lack of efficacy) trial is characterized as a Level A or Level B evidence-based preventive treatment (medications or a MAB or preventive gepant) for migraine preventive trial taken for a minimum of 2 months, at a minimally adequate dose, that produced less than 50% improvement in MMD reduction). Failure to tolerate a preventive treatment does not constitute a preventive treatment failure. History of other chronic headache conditions such as Chronic tension-type headache, Medication Overuse Headache, New Daily Persistent Headache, and Cluster Headache in the prior 6 months. Use of opiates or barbiturates medications in the prior 3 months. Received parenteral infusions for migraine within the previous 2 weeks. Subject has known uncontrolled epilepsy. History of neuro-interventional procedures such as nerve blocks (within the last month), Botulinum Toxin (within the last 3-months), neurosurgical interventions in the head or neck, or implanted/wearable neurostimulators, electronic devices in the head, cardiac pacemaker, surgical clips above the shoulder line or medical pumps, except for dental implants. Current drug abuse or alcoholism. Subjects participating in other clinical trials evaluating experimental treatments or procedures. Skin lesion, scars, or inflammation in the region of the stimulating electrodes. Personality or somatoform disorder. Pregnancy or Lactation. Women of reproductive age not using a reliable contraceptive method, as determined by the Investigator (NOTE: Females of childbearing potential must have a negative pregnancy test). Documented history of cerebrovascular event. Subject with a recent history of traumatic brain injury (TBI), defined as a disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury, within 3 months of study enrollment. Subjects who demonstrate or have a history of any cognitive disorder or impairment, memory loss, dementia, confusion or delirium that, in the opinion of the Investigator, may compromise the integrity of the study data or impact the ability of the subject to comply with the study requirements. Subject diagnosed with other chronic pain disorder which in the opinion of the Investigator may compromise the integrity of the study data or impact the ability of the subject to comply with the study requirements. The subject does not have the basic cognitive and motor skills needed to operate a smartphone. Subject with head circumference smaller than 51 centimeters or head circumference larger than 60 centimeters.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Michal Kedar-Datel
    Phone
    +972-9-3730288
    Email
    michal.kedar-datel@neurolief.com
    First Name & Middle Initial & Last Name or Official Title & Degree
    Yaron Gruper
    Email
    Yaron.Gruper@neurolief.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Stewart J Tepper, MD
    Organizational Affiliation
    Dartmouth-Hitchcock Medical Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine

    We'll reach out to this number within 24 hrs